NO20002038L - Uløselige insulinsammensetninger - Google Patents

Uløselige insulinsammensetninger

Info

Publication number
NO20002038L
NO20002038L NO20002038A NO20002038A NO20002038L NO 20002038 L NO20002038 L NO 20002038L NO 20002038 A NO20002038 A NO 20002038A NO 20002038 A NO20002038 A NO 20002038A NO 20002038 L NO20002038 L NO 20002038L
Authority
NO
Norway
Prior art keywords
acylated
insulin
nph
preparations
present
Prior art date
Application number
NO20002038A
Other languages
English (en)
Other versions
NO20002038D0 (no
Inventor
Mark Laurence Brader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20002038D0 publication Critical patent/NO20002038D0/no
Publication of NO20002038L publication Critical patent/NO20002038L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse gjelder uløselige sammensetninger som inneholder acylerte proteiner utvalgt fra gruppen som består av acylert insulin, acylert insulinanalog og acylert proinsulin, samt preparater av disse. Preparatene er egnet for parenteral tilførsel eller tilførsel på andre måter til en pasient for forlenget kontroll av glukosenivået i blodet. Nærmere bestemt gjelder foreliggende oppfinnelse preparater som omfatter et acylert protein i kompleks med sink, protamin og en fenolisk forbindelse, slik at det resulterende mikrokrystall er analog med krystallformen til nøytralt protamin Hagedorn (NPH) insulin. Det har overraskende blitt oppdaget at preparater av slike acylerte proteiner har terapeutisk overlegne subkutane frigivelsesfarmakokinetiske egenskaper og gir mer forlenget og flatere glukodynamikk enn for tiden tilgjengelige kommersielle preparater av NPH-insulin. Likevel bibeholder de foreliggende krystaller visse fordel- aktige egenskaper ved NPH-krystaller ved at de lett kan resuspenderes og at de også er blandbare med løselige insuliner.
NO20002038A 1997-10-24 2000-04-18 Uløselige insulinsammensetninger NO20002038L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6310497P 1997-10-24 1997-10-24
US8893098P 1998-06-11 1998-06-11
PCT/US1998/022434 WO1999021578A1 (en) 1997-10-24 1998-10-22 Insoluble insulin compositions

Publications (2)

Publication Number Publication Date
NO20002038D0 NO20002038D0 (no) 2000-04-18
NO20002038L true NO20002038L (no) 2000-06-26

Family

ID=26743043

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002038A NO20002038L (no) 1997-10-24 2000-04-18 Uløselige insulinsammensetninger

Country Status (21)

Country Link
US (3) US6268335B1 (no)
EP (1) EP1039920A4 (no)
JP (2) JP2001521006A (no)
KR (1) KR20010024556A (no)
CN (1) CN1276731A (no)
AR (1) AR020047A1 (no)
AU (2) AU747926B2 (no)
BR (1) BR9813111A (no)
CA (2) CA2306905A1 (no)
CO (1) CO4970769A1 (no)
EA (1) EA200000453A1 (no)
HR (1) HRP20000236A2 (no)
HU (1) HUP0004169A3 (no)
ID (1) ID24890A (no)
IL (1) IL134901A0 (no)
NO (1) NO20002038L (no)
PE (1) PE123799A1 (no)
PL (1) PL340255A1 (no)
SV (1) SV1998000125A (no)
TR (1) TR200001050T2 (no)
WO (2) WO1999021578A1 (no)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20020155614A1 (en) * 2001-02-21 2002-10-24 Tomlinson Andrew J. Peptide esterification
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
WO2003024425A1 (en) * 2001-09-19 2003-03-27 Elan Pharma International, Ltd. Nanoparticulate insulin formulations
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
SK2432004A3 (sk) * 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
WO2004080481A1 (en) * 2003-03-13 2004-09-23 Novo Nordisk A/S Novel nph insulin preparations
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
EP2085406A1 (en) * 2003-07-25 2009-08-05 ConjuChem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
CA2910494C (en) * 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US20100216690A1 (en) * 2005-03-18 2010-08-26 Novo Nordisk A/S Pegylated Single-Chain Insulin
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2007134151A2 (en) * 2006-05-10 2007-11-22 Smithkline Beecham Corporation Composition and method for increasing cell permeability of a compound
WO2007135118A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
WO2008034881A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
WO2008043033A2 (en) * 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
CN101674812B (zh) 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2708554A1 (en) * 2007-08-15 2014-03-19 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
RU2453332C2 (ru) 2007-10-16 2012-06-20 Байокон Лимитид Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
AU2009203810B2 (en) * 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
WO2009129250A2 (en) * 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
CN102065885A (zh) * 2008-04-22 2011-05-18 卡斯西部储备大学 同种型特异性的胰岛素类似物
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) * 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
CA2750262C (en) 2009-01-28 2016-08-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
WO2011034629A1 (en) * 2009-02-05 2011-03-24 Abbott Diabetes Care Inc. Devices and methods for metering insoluble active agent particles
US8623345B2 (en) 2009-03-20 2014-01-07 Smartcells Terminally-functionalized conjugates and uses thereof
SG10201403840VA (en) 2009-07-06 2014-10-30 Sanofi Aventis Deutschland Aqueous insulin preparations containing methionine
TW201113032A (en) * 2009-07-06 2011-04-16 Sanofi Aventis Deutschland Slow-acting insulin preparations
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
SI2498802T1 (sl) 2009-11-13 2015-05-29 Sanofi-Aventis Deutschland Gmbh Farmacevtski sestavek, ki vsebuje agonist GLP-1, inzulin in metionin
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
CN102762589A (zh) * 2009-12-11 2012-10-31 卡斯西部储备大学 带有氯化氨基酸的胰岛素类似物
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN102985440B (zh) * 2010-06-23 2016-10-26 诺沃-诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6058646B2 (ja) 2011-06-15 2017-01-11 ノヴォ ノルディスク アー／エス 多置換インスリン
CA2846413C (en) 2011-08-29 2021-11-02 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CN110354255B (zh) 2013-04-03 2024-05-14 赛诺菲 通过长效胰岛素制剂治疗糖尿病
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
RU2016132340A (ru) * 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
EP3091965A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CA2932877A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CA2957714A1 (en) * 2014-08-11 2016-02-18 Albany Medical College Myristoylated leptin-related peptides and uses thereof
JP6829928B2 (ja) 2014-10-06 2021-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 二相性単鎖インスリン類似体
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
ES2908373T3 (es) * 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
JP2019530473A (ja) * 2016-09-06 2019-10-24 ケミカル アンド バイオファーマスーティカル ラボラトリーズ オブ パトラ エス．エー．Ｃｈｅｍｉｃａｌ ＆ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌ Ｌａｂｏｒａｔｏｒｉｅｓ Ｏｆ Ｐａｔｒａｓ Ｓ．Ａ． プロインスリン誘導体
WO2018104346A1 (en) 2016-12-05 2018-06-14 Nuritas Limited Compositions comprising peptide wkdeagkplvk
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
DK3554534T3 (da) 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
US20200147215A1 (en) * 2017-04-24 2020-05-14 Simon H. Friedman Drug conjugates with photocleavable solubility modulators
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
WO2019222221A1 (en) * 2018-05-14 2019-11-21 Dance Biopharm Inc. Insulin formulations for reconstitution into high concentration liquid solutions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US11098102B2 (en) 2018-12-11 2021-08-24 Sanofi Insulin conjugates
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
JP7518149B2 (ja) 2019-07-12 2024-07-17 ノヴォ ノルディスク アー／エス 高濃度インスリン製剤
IL319162A (en) 2019-12-11 2025-04-01 Novo Nordisk As New insulin analogs and their use
EP4126058A1 (en) 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
AU2021273262A1 (en) * 2020-05-15 2022-12-08 Eli Lilly And Company Extended time action acylated insulin compounds
PH12023500012A1 (en) 2020-11-19 2024-03-11 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
EP4255469A4 (en) * 2020-12-07 2025-01-22 Case Western Reserve University ACYLATED SINGLE-CHAIN INSULIN ANALOGUES
PE20251287A1 (es) 2022-05-18 2025-05-14 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina relacionados

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3865325A (en) 1971-07-02 1975-02-11 Dylaker Computer Systems Inc Flexible tape reel
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
US4343898A (en) 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
JPS58501455A (ja) 1981-09-15 1983-09-01 ノルデイスク　インシユリンラボラトリユ−ム 人インシユリンまたはそのｂ−３０エステルの製造法
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
JPH03506023A (ja) 1988-07-20 1991-12-26 ノボ　ノルデイスク　アクツイエセルスカプ ポリペプチド
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
DE122006000017I1 (de) 1993-06-21 2006-06-29 Novo Nordisk As ASP-B28-Insulinkristalle
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
DK0792290T3 (da) 1993-09-17 2001-10-01 Novo Nordisk As Acyleret insulin
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
WO1996029344A1 (en) * 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
PL188736B1 (pl) 1996-06-20 2005-04-29 Novo Nordisk As Wodny preparat insuliny oraz sposób jego przygotowania
DE69829953T2 (de) 1997-02-07 2006-03-02 Novo Nordisk A/S Kristallisation von proteinen
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.

Also Published As

Publication number Publication date
EA200000453A1 (ru) 2000-10-30
JP2001521004A (ja) 2001-11-06
JP2001521006A (ja) 2001-11-06
BR9813111A (pt) 2000-08-15
EP1039920A1 (en) 2000-10-04
IL134901A0 (en) 2001-05-20
KR20010024556A (ko) 2001-03-26
WO1999021573A1 (en) 1999-05-06
NO20002038D0 (no) 2000-04-18
US6268335B1 (en) 2001-07-31
HRP20000236A2 (en) 2001-02-28
PE123799A1 (es) 1999-12-13
AU1111799A (en) 1999-05-17
AR020047A1 (es) 2002-04-10
WO1999021578A1 (en) 1999-05-06
US20010036916A1 (en) 2001-11-01
AU1116699A (en) 1999-05-17
TR200001050T2 (tr) 2000-08-21
HUP0004169A3 (en) 2001-06-28
ID24890A (id) 2000-08-31
AU747926B2 (en) 2002-05-30
CO4970769A1 (es) 2000-11-07
CA2306877A1 (en) 1999-05-06
PL340255A1 (en) 2001-01-29
CN1276731A (zh) 2000-12-13
US6465426B2 (en) 2002-10-15
SV1998000125A (es) 1999-05-24
CA2306905A1 (en) 1999-05-06
US20020082199A1 (en) 2002-06-27
HUP0004169A2 (hu) 2001-05-28
EP1039920A4 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
NO20002038L (no) Uløselige insulinsammensetninger
AU612141B2 (en) Novel insulin derivatives
FI79786C (fi) Foerfarande foer framstaellning ett farmaceutiskt medel foer behandling av diabetes.
EA200000708A1 (ru) Нерастворимые композиции, применяемые для регулирования концентрации глюкозы в крови
ATE482717T1 (de) Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
US20120316107A1 (en) Fibrillation-resistant insulin and insulin analogues
Dissing et al. Human red cell acid phosphatase (ACP1). The amino acid sequence of the two isozymes Bf and Bs encoded by the ACP1* B allele.
IE841947L (en) Crystal suspensions of insulin derivatives
CA2494241A1 (en) Botulinum toxin pharmaceutical compositions
HUT58349A (en) Process for producing new isoleucine derivatives
NO179587B (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv insulinanalog og mellomprodukt
DK159856B (da) Humaninsulinderivater og farmaceutiske praeparater, som indeholder disse derivater
IL148942A (en) Pre-insulin with C-peptide modified for improved insulin production and insulin analogues
MXPA05000412A (es) Formulacioneks liquidas con una alta concentracion de hormona de crecimiento humana (hgh) que comprenden glicina.
US10745458B2 (en) Non-standard insulin analogues
CA2683317C (en) Stabilization of liquid solutions of recombinant protein for frozen storage
Fry et al. Isolation and partial characterization of a chromophore-peptide fragment from pepsin digests of phytochrome
Carpenter et al. Long‐Term Storage of Proteins
BAHL Chemistry of human chorionic gonadotropin
US5049545A (en) Insulin derivatives, a process for their preparation, and their use
EP0911035A3 (en) Insoluble insulin compositions
Sherwood et al. Crystallization and preliminary diffraction data for iso-1-cytochrome c from yeast
WO2000047721A3 (en) Methods of inducing insulin positive progenitor cells
ES2270827T3 (es) Uso de procarboxipeptidasa b pancreatica para la produccion de insulina.
NZ196610A (en) Preparation of insulin or insulin analog

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application